Lead Program LSR-1019 is a Proprietary Sublingual Formulation of 5-MeO-DMT, a Potent, Fast-Acting and Rapidly Clearing Psychedelic, in Development for Treatment-Resistant Depression and Other Neuropsychiatric Indications RA Capital Management Incubated the Company and Led the Series A Financing with Participation from Venrock Healthcare Capital Partners, Deep Track Capital…


Previous articleatai Life Sciences to Participate in November Investor Events & Healthcare Conferences
Next articleApex Labs Granted Approval for North America’s First Take Home Psilocybin Clinical Trial